4528.T实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 14:15):

Stats
今日成交量	3.19M
平均成交量	2.18M
市值	1 048.85B
EPS	¥0 ( 2024-01-30 )
下一个收益日期	( ¥51.38 ) 2024-05-08
Last Dividend	¥37.00 ( 2023-03-30 )
Next Dividend	¥0 ( N/A )
P/E	8.71
ATR14	¥1.094 (0.05%)

音量相关性

長: 0.27 (neutral)

短: 0.04 (neutral)

Signal:(50.934) Neutral

Ono Pharmaceutical Co., 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Ono Pharmaceutical Co., 相关性 - 货币/商品

0.35
( neutral )

0.46
( neutral )

0.06
( neutral )

0.56
( weak )

-0.35
( neutral )

-0.22
( neutral )

Ono Pharmaceutical Co., 财务报表

Annual	2022
营收:	¥447.19B
毛利润:	¥337.13B (75.39 %)
EPS:	¥230.85

FY	2022
营收:	¥447.19B
毛利润:	¥337.13B (75.39 %)
EPS:	¥230.85

FY	2022
营收:	¥361.36B
毛利润:	¥267.85B (74.12 %)
EPS:	¥162.19

FY	2021
营收:	¥309.28B
毛利润:	¥223.71B (72.33 %)
EPS:	¥151.11

Financial Reports:

No articles found.

Ono Pharmaceutical Co., Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥33.00 (N/A)	¥0 (N/A)	¥37.00 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

Ono Pharmaceutical Co., Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 5.64 - Stable (12.82%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	¥6.80	2001-03-27
Last Dividend	¥37.00	2023-03-30
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	41	--
Total Paid Out	¥671.50	--
Avg. Dividend % Per Year	0.00%	--
Score	4.16	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	5.64
Div. Directional Score	9.16	--

Next Divdend (Est)
(2024-10-14)

¥0 Estimate 0.00 %

Dividend Stability

0.09 Very Bad

Dividend Score

4.16

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
8140.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
7494.T	Ex Dividend Junior	2023-09-28	Semi-Annually	0.00%
6718.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
6062.T	Ex Dividend Knight	2024-06-27	Annually	0.00%
4743.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
3984.T	Ex Dividend Junior	2024-06-27	Annually	0.00%
3193.T	Ex Dividend Junior	2024-01-30	Annually	0.00%
2183.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
9058.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
7944.T	Ex Dividend Knight	2023-12-28	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.256	1.500	4.88	7.31	[0 - 0.5]
returnOnAssetsTTM	0.143	1.200	5.23	6.28	[0 - 0.3]
returnOnEquityTTM	0.166	1.500	9.26	10.00	[0.1 - 1]
payoutRatioTTM	0.291	-1.000	7.09	-7.09	[0 - 1]
currentRatioTTM	3.95	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	3.19	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	1.140	1.500	4.78	7.17	[0.2 - 2]
debtRatioTTM	0.00963	-1.500	9.84	-10.00	[0 - 0.6]
interestCoverageTTM	99.03	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	222.86	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	191.88	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.0109	-1.500	9.96	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.756	1.000	0.740	0.740	[0.2 - 0.8]
operatingProfitMarginTTM	0.329	1.000	5.41	5.41	[0.1 - 0.6]
cashFlowToDebtRatioTTM	12.35	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.559	0.800	9.61	7.69	[0.5 - 2]
Total Score				12.67

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	8.58	1.000	9.23	0	[1 - 100]
returnOnEquityTTM	0.166	2.50	9.53	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	191.88	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	3.48	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	222.86	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0.291	1.500	7.09	-7.09	[0 - 1]
pegRatioTTM	-1.449	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.213	1.000	7.18	0	[0.1 - 0.5]
Total Score				5.64

Ono Pharmaceutical Co.,

Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER capsules for improvement of the symptoms in patients with pheochromocytoma; and MEKTOVI, VELEXBRU, and ADLUMIZ tablets, as well as BRAFTOVI capsules for malignant tumors. The company also provides GLACTIV and FORXIGA tablets for type 2 diabetes; FORXIGA tablets for the treatment of diabetes; ONOACT injections for tachyarrhythmia; OPALMON tablets to treat peripheral circulatory disorder; CORALAN for treatment of chronic heart failure; ORENCIA injections for rheumatoid arthritis; RIVASTACH patches for Alzheimer's disease; ONGENTYS tablets for the treatment of Parkinson's disease; PARSABIV, an intravenous injection for dialysis patients; STAYBLA tablets for overactive bladder; ONON capsules and dry syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as RECALBON tablets for osteoporosis. In addition, it is developing products for esophageal, urothelial carcinoma, Hodgkin's lymphoma, ovarian, bladder, prostate, hepatocellular carcinoma, pancreatic, biliary tract, virus positive/negative solid carcinoma, gastric, esophageal, urothelial, hepatocellular, thyroid, colorectal, melanoma, acute myeloid leukemia, non-small cell lung cancer, primary central nervous system lymphoma, myelodysplastic syndrome, polymyositis/dermatomyositis, tachyarrhythmia, pemphigus, generalized scleroderma, enthesopathy, diabetic polyneuropathy, neurodegenerative, autoimmune, narcolepsy, and thrombosis. The company was founded in 1717 and is headquartered in Osaka, Japan.